Introduction: The prevalence of carcinoid heart disease (CaHD) in bronchopulmonary carcinoid and its relationship with left-sided valvular disease are unknown.
Introduction
Bronchopulmonary carcinoid tumors are an uncommon malignant neuroendocrine neoplasm that represents 1% to 2% of lung cancer and 10% to 33% of all carcinoid tumors. 1 Carcinoid syndrome is a rare paraneoplastic syndrome characterized by flushing, diarrhea, and wheezing resulting from the systemic release of histamine, prostaglandin, and particularly, serotonin. This syndrome commonly develops when liver metastases are present. 2 Compared to carcinoid tumors of small bowel origin, bronchopulmonary carcinoid is more often localized and less likely to be associated with liver metastases. 1, 2 Carcinoid heart disease (CaHD) develops in approximately 20% of patients with carcinoid syndrome and is associated with a worse prognosis. It is thought to be the result of chronic exposure to high levels of circulating serotonin, which causes valvular fibrosis with leaflet retraction and thickening. 3 CaHD typically affects the right-sided heart valves resulting in regurgitation, stenosis, or both. Left-sided valvular involvement has been observed in up to 15% of patients with CaHD and attributed to the presence of a patent *Corresponding author.
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foramen ovale (PFO), marked carcinoid activity, or bronchopulmonary tumor. The lower incidence of leftsided valvular heart disease was hypothesized to be a result of pulmonary deactivation of circulating serotonin metabolites by monoamine oxidases. 3, 4 No prior study has reported the prevalence of CaHD in bronchopulmonary carcinoid. This study aimed to estimate the prevalence of CaHD in patients with bronchopulmonary carcinoid and to determine if it has a predilection for left-sided valves.
Clinical Material and Methods
A retrospective review of all patients with a pathologic diagnosis of bronchopulmonary carcinoid and an echocardiogram performed at our institution from 2001 through 2016 was conducted. All patients underwent chest computed tomography with inclusion of the liver and adrenal glands within the imaging field. When liver lesions were present, this computed tomographic scan was followed by either hepatic ultrasound or magnetic resonance imaging. The study was approved by the Institutional Review Board.
Echocardiograms performed within 30 days before or after the diagnosis of bronchopulmonary carcinoid were included. Echocardiographic features of CaHD were assessed according to literature. [5] [6] [7] Patient characteristics are expressed as mean (SD), median (intraquartile range [IQR]) or number (%). Wilcoxon test was used to compare differences between nonparametric variables. A value of p < 0.05 was considered significant.
Results
The records of 513 patients with a pathologic diagnosis of bronchopulmonary carcinoid were reviewed to identify 203 patients who underwent echocardiography. Pathologic diagnosis was made by biopsy in 106 patients (52%) and by tumor resection in 97 (48%). After the exclusion of 19 patients with echocardiography more than 30 days before the initial diagnosis of bronchopulmonary carcinoid, 185 patients were included. Of these, 19 patients underwent echocardiography as part of their perioperative workup. In the remaining 166 patients, the median echocardiographic follow-up was 51.5 months (IQR: 9.3 to 91.2 months, maximum 358.6 months). Clinical characteristics are shown in Table 1 . The median peak 24-hour urinary 5-hydroxyindoleacetic acid (5-HIAA) was 5.2 mg/24 h (IQR: 3.5 to 6.7 mg/24 h) (normal 8 mg/24 h), 4.8 mg/24 h (IQR: 3.3 to 5.9 mg/24 h) in patients with liver metastasis, and 7.3 mg/24h (IQR: 5.4 to 68 mg/24 h) in patients with carcinoid syndrome.
Carcinoid tumor was the indication for echocardiography in 33 patients (18%). Other indications included cardiac symptoms (20%), coronary artery disease (14%), pre-operative assessment (11%), noncarcinoid valvular heart disease (10%), arrhythmias (6%), pulmonary hypertension (6%), pre-chemotherapy assessment (4%), nonischemic cardiomyopathy (4%), and other (7%). Echocardiographic features of CaHD were present in 2 (1%) patients. Neither had measurement of N terminal-pro-brain natriuretic peptide (NT-proBNP).
One patient was a 62-year-old woman who underwent resection of stage 1A bronchopulmonary carcinoid without carcinoid syndrome and also received therapy for 7 months with dexfenfluramine. 5-HIAA and chromogranin A levels were not measured. The tricuspid valve septal leaflet was mildly thickened and retracted with mild regurgitation and the mitral anterolateral leaflet was thickened and retracted with moderate regurgitation. During 15-year follow-up, mitral regurgitation decreased and tricuspid regurgitation remained stable, a course more consistent with diet-drug-related valve disease than CaHD. 8 The other patient was a 71-year-old woman status post-resection of a grade 1 hilar carcinoid tumor with carcinoid syndrome, liver metastases, and elevated urinary 5-HIAA (80 mg/24 h). Tricuspid and pulmonary valves had typical thickening and retraction with severe regurgitation and mild stenosis. The aortic valve was mildly thickened and retracted with mild regurgitation. A PFO was present. This patient underwent bioprosthetic tricuspid and pulmonary valve replacement with patch enlargement of the pulmonary annulus and PFO closure. Pathologic examination of the resected valves confirmed CaHD (Fig. 1) .
Discussion
CaHD was present in only 1 (0.5%) of 185 patients with bronchopulmonary carcinoid. This patient had right-and left-sided cardiac valvular involvement, hepatic metastases, high urinary 5-HIAA levels, and a PFO. Thus, factors other than the presence of bronchopulmonary origin of tumor may have accounted for the presence of left-sided cardiac valvular involvement. We found no definite evidence of a relationship of bronchopulmonary carcinoid and left-sided valve disease. Most specialized literature attributes left-sided valvar involvement in carcinoid syndrome to the presence of a shunt (usually a PFO), marked carcinoid activity (high levels of circulating serotonin), or the presence of a primary bronchial carcinoid (Table 2) . 4, 6 Recent large case series including patients with bronchopulmonary carcinoid otherwise did not show any incidence of carcinoid syndrome in this subgroup. [9] [10] [11] Several factors could explain these findings. It is well-known that carcinoid tumors from midgut origin (excluding appendiceal tumors) have a higher incidence of carcinoid syndrome in comparison with tumors arising from the foregut structures (bronchi, stomach, and proximal duodenum). Foregut tumors have lower serotonin secretion and consequently lower incidence of carcinoid syndrome. Bronchial carcinoids rarely exhibit secretory activity or metastasize. 12 In our study, the prevalence of carcinoid syndrome was 7.7% (slightly more than what is described in the literature for this type of carcinoid tumor), and there was a modestly higher 24-hour urinary 5-HIAA in patients with carcinoid syndrome alone or in association with liver metastasis. Higher levels have been reported in series of patients with carcinoid syndrome predominantly from tumors of midgut origin. 4, 13 CaHD is known to be related to higher levels of 5-HIAA in comparison with patients without cardiac involvement. 6, 7 The only case of CaHD in our study was in the presence of other known CaHD risk factors (elevated serotonin and hepatic metastases) and it affected the aortic valve in the presence of a PFO.
Current guidelines recommend routine echocardiographic assessment for the presence of CaHD at initial bronchopulmonary carcinoid diagnosis and during follow-up, particularly before surgical intervention. 14 Despite such recommendations, marked variability had been shown in the screening of patients and frequency of repeat surveillance. 15 Our findings suggest that patients with typical early-stage bronchopulmonary carcinoid without liver metastases or carcinoid syndrome are at low risk of CaHD. Hence, routine screening echocardiography may not be necessary.
Conclusion
CaHD occurs in less than 1% of patients with bronchopulmonary carcinoid. Bronchopulmonary carcinoid was not associated with CaHD in the absence of liver metastasis and was not associated with left-sided valve involvement in the absence of PFO. A relationship of left-sided valve involvement and bronchopulmonary carcinoid was not shown. Routine echocardiography does not appear to be indicated in screening of patients with isolated typical, early-stage bronchopulmonary carcinoid unless carcinoid syndrome is present. These data should be interpreted with caution in patients with higher stage or atypical carcinoid disease, given the few patients in these categories.
